Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials.
The increasing knowledge concerning anatomical structures and cellular processes underlying event-related potentials (ERP) as well as methodological advances in ERP data analysis (e.g. dipole source analysis) is beginning to bridge the gap between ERP and neurochemical aspects. Reliable indicators of the serotonin system are urgently needed because of its role in pathophysiology and as target of pharmacotherapeutic interventions in psychiatric disorders. Converging arguments from preclinical and clinical studies support the hypothesis that the loudness dependence of the auditory evoked N1/P2-response (LDAEP) is regulated by the level of central serotonergic neurotransmission. Dipole source analysis represents an important methodological advance in this context, because the two N1/P2-subcomponents, generated by the primary and secondary auditory cortex known to be differentially innervated by serotonergic fibres, can be separated. A pronounced LDAEP of primary auditory cortices is supposed to reflect low central serotonergic neurotransmission, and vice versa. LDAEP is a parameter with potential clinical value since subgroups of patients with a serotonergic dysfunction can be identified and can be treated more specifically. In depressed patients, a significant relationship between strong LDAEP, indicating low serotonergic function, and a favourable response to SSRI has been found. Additionally, there is evidence from several studies with patients with affective disorders that a strong LDAEP predicts favourable response to a preventive lithium treatment.
Hegerl
U
U
Department of Psychiatry, Ludwig-Maximilians-Universität, Nussbaumstr. 7, 80336 München, Germany. uhegerl@psy.med.uni-muenchen.de
Juckel
G
G
D018692:Antimanic Agents / Q000627:therapeutic use; D005072:Evoked Potentials, Auditory / Q000502:physiology*; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D001523:Mental Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D019964:Mood Disorders / Q000517:prevention & control; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D009435:Synaptic Transmission / Q000187:drug effects
D018692:Antimanic Agents; D008094:Lithium; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors